a76df2f9_docrine_Cancer_Research___CFCF__Status
[Title] A Phase II Study to Evaluate the Safety and Efficacy of RAD001 Plus Erlotinib in Patients With Well- to Moderately-Differentiated Neuroendocrine Tumors [Phase] II [Conditions] Neuroendocrine Tumor [State] CA [Status] 
Not Recruiting
N o t R e c r u i t i n g
E n r o l l i n g